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Objective: Androgen deprivation and
androgen targeted therapies (ATT) are
established treatments for prostate cancer
(PCa). Although initially effective, ATT
induces an adaptive response that leads to
treatment resistance. Increased expression
of relaxin-2 (RLN2) is an important alter-
ation in the adaptive response. RLN2 has a
well described role in PCa cell proliferation,
adhesion and tumour growth. The objec-
tives of this study were to develop cell mod-
els for studies of RLN2 signalling and to
implement in vitro assays for evaluating the
therapeutic properties of the unique RLN2
receptor (RXFP1) antagonist.
Methods: To validate the increased
expression of RLN2 after the ATT we
treated LNCaP cells with antiandrogens
and used qPCR to determine its expres-
sion. We established doxycycline inducible
RLN2 and RXFP1 knock-down (KD) and
over-expression (OE) LNCaP models. We
chemically synthesised RXFP1 antagonist
and evaluated its therapeutic properties in
cell proliferation and adhesion assays. To
identify paracrine action of relaxin, we co-
cultured inducible RLN2 KD and OE
LNCaP models on bioengineered osteo-
blast matrices.
Results: We confirmed the increased
expression of RLN2 after ATT in LNCaP
cells. We established and validated induc-
ible RLN2 and RXFP1 KD and OE LNCaP
models. We showed that the KD of RLN2
and RXFP1 inhibited proliferation and
adhesion of LNCaP cells. Our unique
RXFP1 antagonist inhibited proliferation
of LNCaP cells.
Conclusions: Our results show that the
inhibition of relaxin signalling supressed
proliferation and adhesion of PCa cells.
Further confirmation of these findings in a
preclinical model will be crucial step for
translation of the RXFP1 antagonist into
clinics.
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Current translational and basic prostate
cancer research is limited by the number of
cell lines that truly reflect the spectrum of
disease progression, with most commonly
used cell lines being derived from meta-
static lesions. There are essentially no pros-
tate cancer cell lines derived from primary
tumours or localised disease in wide use.
Objective: The objective of this work is to
characterise novel primary tumour derived
epithelial prostate cancer cell lines.
Methods: We have established a number
of new prostate cancer cell lines derived
from radical prostatectomy tissue taken
from men with localised disease. Pathology
of the tissue revealed benign and adeno-
carcinoma phenotypes with Gleason scores
of 6–7 and patient PSA levels of 4–9 ng/
mL. Cells were characterised for lineage
markers, other prostate cancer relevant
targets, STR profiling, RNAseq analysis
and functional assays.
Results: RT-PCR and Western Blot analy-
sis of lineage markers confirmed these
cells are luminal in origin (cytokeratin/
CK8 and 18 positive), with low to no AR
expression. Most were also CK5, CK14
and p63 positive, which are basal markers,
and CD133 negative suggesting a mixed
lineage but not stem cell like. In initial
anchorage independent growth assays, no
growth/colony formation was observed,
however, cells appeared to remain viable.
This phenomenon may be attributed to
their early tumour origins. Further charac-
terisation of these lines is ongoing.
Conclusions: These results show potential
for these cell lines as model for primary/
localised disease. Development of contem-
porary cell lines, particularly from men with
localised prostate cancer, will provide a rep-
ertoire of more clinically relevant research
tools for the prostate cancer community.
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Objective: Androgens and the androgen
receptor (AR) play a crucial role in the
initiation and progression of prostate can-
cer (PCa), regulating the expression of
many PCa risk-associated genes. Iroquois
Homeobox 4 (IRX4) has been recently
identified with PCa risk and overexpressed
in PCa. We observed a down-regulation of
IRX4 expression in the cells undergoing
epithelial to mesenchymal transition, sug-
gesting its potential role in PCa progres-
sion and aim to delineate the androgen-
mediated regulation of IRX4 in PCa.
Methods: In-silico analysis to identify the
transcription factor (TF) binding sites reg-
ulating the IRX4 expression (Cistrome
Finder database), followed by sequencing
of these regions was performed. PCa cell
lines (DuCaP and LNCaP) were treated
with androgens for 48 h and IRX4 expres-
sion was determined by qRT-PCR.
Results: Binding of two crucial TFs – AR
and ERG, was observed upstream of IRX4
in the VCaP cells while there was no AR
binding in LNCaP cells at this locus, sug-
gesting differential androgen responsive-
ness of IRX4. Moreover, IRX4 was
up-regulated by androgens in DuCaP cells,
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